Live attenuated influenza vaccine, trivalent, is safe in healthy children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in a community-based, nonrandomized, open-label trial.
about
Vaccines for preventing influenza in people with asthmaWheeze as an adverse event in pediatric vaccine and drug randomized controlled trials: A systematic reviewThe population impact of a large school-based influenza vaccination campaignSafety and immunogenicity following administration of a live, attenuated monovalent 2009 H1N1 influenza vaccine to children and adults in two randomized controlled trialsEfficacy of trivalent, cold-adapted, influenza virus vaccine against influenza A (Fujian), a drift variant, during 2003-2004Statewide school-located influenza vaccination program for children 5-13 years of age, Hawaii, USA.Aerosol and nasal delivery of vaccines and antiviral drugs against seasonal and pandemic influenza.Optimizing vaccine allocation at different points in time during an epidemic.Optimal vaccine allocation for the early mitigation of pandemic influenza.Vaccinating to protect a vulnerable subpopulation.Direct and indirect effectiveness of influenza vaccination delivered to children at school preceding an epidemic caused by 3 new influenza virus variants.Vaccination of children with a live-attenuated, intranasal influenza vaccine - analysis and evaluation through a Health Technology AssessmentRelative timing of influenza disease by age group.School-located influenza vaccination reduces community risk for influenza and influenza-like illness emergency care visits.Immunogenicity of trivalent influenza vaccine in extremely low-birth-weight, premature versus term infantsAn integrated, multistudy analysis of the safety of Ann Arbor strain live attenuated influenza vaccine in children aged 2-17 years.Mucosal inoculation with an attenuated mouse pneumovirus strain protects against virulent challenge in wild type and interferon-gamma receptor deficient mice.Increased risk of noninfluenza respiratory virus infections associated with receipt of inactivated influenza vaccineInfluenza and the challenge for immunology.Establishing the baseline burden of influenza in preparation for the evaluation of a countywide school-based influenza vaccination campaign.Club cells surviving influenza A virus infection induce temporary nonspecific antiviral immunity.Maternal outcomes among pregnant women receiving live attenuated influenza vaccine.Assessing the safety of influenza vaccination in specific populations: children and the elderly.Hospitalizations within 14days of vaccination among pediatric recipients of the live attenuated influenza vaccine, United States 2010-2012.Implementing and sustaining school-located influenza vaccination programs: perspectives from five diverse school districts.Pan-Influenza A Protection by Prime-Boost Vaccination with Cold-Adapted Live-Attenuated Influenza Vaccine in a Mouse Model.Live Attenuated Influenza Vaccination Prior To Age 3 Years and Subsequent Development of Asthma: A 14-Year Follow-Up Study.Alternative routes of influenza vaccine delivery
P2860
Q24200871-FCF96BF8-4798-4BD3-BB1E-A3A287CA22DBQ26796334-6A200EC2-38D2-4758-8716-031D7D847B0BQ28743825-299F7A64-6AB9-437B-B7A0-7A2C2B808351Q28748654-1BA78D1E-3E5B-49A1-B5B9-EE71C32A4ABBQ30360764-3F6D30C5-D51D-4C24-9058-A5AE3523D0ADQ30385051-2C28FF06-20DD-4801-8CFE-7A7FEACAA2BAQ30388296-0DB1D664-F507-4A4F-B543-AA1EE6509484Q30396382-EF868650-C73B-4464-A15A-3653EB552C59Q30428994-92DEF83B-DAD9-46B0-9F22-1DDF307B7CB5Q33285392-418D869F-1DDB-4C9E-9F34-4D4551FB7DF8Q34279996-806C9CCB-D832-47A6-B030-0DB455BD3B37Q34446848-254C2DC1-112A-4F03-A722-C17F5CE0FCEDQ34613067-717261EE-60FB-4C71-A664-29B1208755FFQ34663046-9F249C0E-D8C2-45B4-836C-23FA0F5DB3FBQ34960945-0D20C415-0532-4C5B-B25D-26D0E43163EDQ35667079-54F8F176-22F8-48C8-9DAF-426E8FA09C22Q35897408-CCC9186A-AA66-4727-AC2D-094914151F47Q36115609-0033B723-DFBF-482F-8B8E-144B7936E057Q36452600-98C10704-4B41-4ABF-91A2-2C7F072F1AE9Q36759964-E602205F-DB92-4C3D-AC91-EE74AEDD6D68Q36802513-BCA410BB-4F86-4BF2-AC0B-0695B1F8C8DCQ37086850-FD75F547-9A03-4AC0-93C4-C51BD976ABCFQ38045920-1EA46F9E-CFF9-4B1F-9380-E615EBC377CDQ38403505-53746590-7E8B-4934-BAF5-21006372AB63Q42596457-BCF986DF-9253-476A-9092-BCC22C0D25A0Q49465358-7043BB38-FBF4-40EF-B151-15CFA26C15C0Q50071104-DA70FA9B-E6B4-4E9E-AFD6-30E427028D6CQ57114644-B1D4AD3D-66F5-4B7B-A78A-ED9C89931F3F
P2860
Live attenuated influenza vaccine, trivalent, is safe in healthy children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in a community-based, nonrandomized, open-label trial.
description
2005 nî lūn-bûn
@nan
2005 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Live attenuated influenza vacc ...... nrandomized, open-label trial.
@ast
Live attenuated influenza vacc ...... nrandomized, open-label trial.
@en
Live attenuated influenza vacc ...... nrandomized, open-label trial.
@nl
type
label
Live attenuated influenza vacc ...... nrandomized, open-label trial.
@ast
Live attenuated influenza vacc ...... nrandomized, open-label trial.
@en
Live attenuated influenza vacc ...... nrandomized, open-label trial.
@nl
prefLabel
Live attenuated influenza vacc ...... nrandomized, open-label trial.
@ast
Live attenuated influenza vacc ...... nrandomized, open-label trial.
@en
Live attenuated influenza vacc ...... nrandomized, open-label trial.
@nl
P2093
P2860
P356
P1433
P1476
Live attenuated influenza vacc ...... nrandomized, open-label trial.
@en
P2093
Charles Fewlass
Claudia Kozinetz
Colin Hessel
Gayla Herschler
Manjusha J Gaglani
Mark Riggs
Matt Watts
Pedro A Piedra
W Paul Glezen
P2860
P304
P356
10.1542/PEDS.2004-2258
P407
P577
2005-09-01T00:00:00Z